Gonadorelin vs Triptorelin

Synthetic GnRH that binds pituitary GnRH receptors; pulsatile dosing stimulates LH/FSH release; used to maintain HPG axis during TRT

Gonadorelin is the synthetic form of endogenous gonadotropin-releasing hormone (GnRH), the hypothalamic decapeptide that drives the pulsatile reproductive axis by stimulating pituitary release of LH and FSH. When delivered in a pulsatile pattern mimicking the hypothalamic pulse generator, gonadorelin effectively restores normal gonadotropin secretion and reproductive function in individuals with hypothalamic hypogonadism. Peer-reviewed clinical studies demonstrate efficacy of pulsatile gonadorelin pump therapy for testosterone restoration in men with congenital hypogonadotropic hypogonadism, as well as for ovulation induction in women with hypothalamic amenorrhea. Gonadorelin is a prescription peptide requiring specialist oversight; continuous rather than pulsatile administration produces paradoxical gonadotropin suppression, making context of use clinically critical. Gonadorelin dosage in TRT support contexts: in men on testosterone replacement therapy, gonadorelin is commonly used off-label to maintain testicular function and endogenous testosterone production capacity. Subcutaneous doses of 100 mcg administered twice weekly are frequently cited in TRT clinical protocols for this purpose — injected at a pulsatile rather than continuous delivery pattern to preserve LH/FSH signaling. This application requires physician supervision due to the dose-timing sensitivity; the paradoxical suppression from continuous dosing is a clinically important consideration that distinguishes gonadorelin from simpler TRT adjuncts. Gonadorelin vs hCG: both are used in men's health contexts to maintain testicular function alongside testosterone therapy, but they act at different levels of the HPG axis. hCG acts directly at the Leydig cell LH receptor to drive testicular testosterone production, bypassing the pituitary. Gonadorelin acts at the pituitary to stimulate endogenous LH and FSH release — preserving the full hypothalamic-pituitary axis rather than just the downstream testosterone signal. The clinical distinction matters for fertility: gonadorelin preserves FSH stimulation of sperm production alongside testosterone, while hCG stimulates testosterone without independently driving FSH. Telehealth hormone therapy providers offering gonadorelin are listed in the PeptideBase directory.

Potent GnRH agonist; single pulse stimulates LH/FSH surge and restores HPG axis after suppression (e.g., post-steroid cycle)

Triptorelin is a synthetic decapeptide GnRH agonist with a longer half-life than endogenous GnRH, used clinically to produce controlled hormonal suppression of the reproductive axis via receptor downregulation. Unlike the brief stimulatory effect of native GnRH, continuous or depot administration of triptorelin paradoxically desensitizes pituitary GnRH receptors, producing sustained suppression of LH, FSH, and sex hormone levels through a process known as medical castration. Clinical trials have established triptorelin efficacy for androgen deprivation therapy in prostate cancer, treatment of central precocious puberty, and hormonal management of endometriosis and uterine fibroids. Triptorelin is an FDA-approved prescription medication (Trelstar) available in depot formulations; it requires specialist-supervised monitoring due to an initial hormonal flare on commencement and the significant physiological effects of prolonged sex hormone suppression. Triptorelin for HPTA restart (PCT context) Outside its approved indications, triptorelin has been discussed in post-cycle therapy (PCT) and testosterone replacement therapy (TRT) restart contexts. The rationale is mechanistic: a single low dose of triptorelin triggers a brief, intense LH and FSH pulse before inducing pituitary downregulation — this initial agonist surge may be sufficient to re-sensitise a suppressed hypothalamic-pituitary-gonadal (HPG) axis following prolonged androgen administration that has blunted endogenous LH/FSH production. Some research and anecdotal literature describes single-dose triptorelin protocols (typically 100–200mcg administered once) as an HPTA restart approach, with the goal of re-initiating endogenous testosterone production. This use is not FDA-approved, not evaluated in randomised controlled trials for this indication, and not a standard of care in any guideline. It represents an off-label research and community-practice area. Triptorelin's mechanism — producing sustained hormonal suppression — means that incorrect dosing or repeated administration would achieve the opposite of the desired restart effect; this context requires qualified clinical supervision. PeptideBase does not endorse off-label use; this is informational context about how the compound is discussed in research and clinical community settings.